The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Conditions similar to those of the Miller–Urey experiments are present in other regions of the Solar System, often substituting ultraviolet light for lightning as the energy source for chemical reactions. The Murchison meteorite that fell near Murchison, Victoria, Australia in 1969 was found to contain an amino acid distribution remarkably similar to Miller–Urey discharge products. Analysis of the organic fraction of the Murchison meteorite with Fourier-transform ion cyclotron resonance mass spectrometry detected over 10,000 unique compounds, albeit at very low (ppb–ppm) concentrations. In this way, the organic composition of the Murchison meteorite is seen as evidence of Miller–Urey synthesis outside Earth. Comets and other icy outer-solar-system bodies are thought to contain large amounts of complex carbon compounds (such as tholins) formed by processes akin to Miller–Urey setups, darkening surfaces of these bodies. Some argue that comets bombarding the early Earth could have provided a large supply of complex organic molecules along with the water and other volatiles, however very low concentrations of biologically-relevant material combined with uncertainty surrounding the survival of organic matter upon impact make this difficult to determine.
On 11 January 1922, Leonard Thompson, a 14-year-old diabetic who lay dying at the Toronto General Hospital, was given the first injection of insulin. However, the extract was so impure that Thompson had a severe allergic reaction, and further injections were cancelled. Over the next 12 days, Collip worked day and night to improve the ox-pancreas extract. A second dose was injected on 23 January, eliminating the glycosuria that was typical of diabetes without causing any obvious side-effects. The first American patient was Elizabeth Hughes, the daughter of U.S. Secretary of State Charles Evans Hughes. The first patient treated in the U.S. was future woodcut artist James D. Havens; John Ralston Williams imported insulin from Toronto to Rochester, New York, to treat Havens. Banting and Best never worked well with Collip, regarding him as something of an interloper, and Collip left the project soon after. Over the spring of 1922, Best managed to improve his techniques to the point where large quantities of insulin could be extracted on demand, but the preparation remained impure. The drug firm Eli Lilly and Company had offered assistance not long after the first publications in 1921, and they took Lilly up on the offer in April. In November, Lilly's head chemist, George B. Walden discovered isoelectric precipitation and was able to produce large quantities of highly refined insulin. Shortly thereafter, insulin was offered for sale to the general public.
While there are many rehabilitation centres for wealthy people struggling with addiction in South Africa there are very few facilities for the poor. Some have argued that people struggling with heroin addiction are treated as the 'undeserving poor' and subject to policing rather than medical interventions. In the populous province of KwaZulu-Natal there are only two government rehab centres accessible by poor people.
Generally, monazite performs better in recording metamorphism (recrystallisation ages) with different zonation patterns in ages and composition. Zircon is not as reactive as monazite during metamorphic reactions and is better for recording igneous events (cooling ages). Moreover, monazite is more suitable in dating relatively low-temperature metamorphism for example amphibolite-facies than zircon.
Sources: en.wikipedia.org
Agriculture was once the most important industry in Denmark. Nowadays, it is of minor economic importance. In 2016, 62,000 people, or 2.5% of all employed people worked in agriculture and horticulture. Another 2,000 people worked in fishing. As value added per person is relatively low, the share of national value added is somewhat lower. Total gross value added in agriculture, forestry and fishing amounted to 1.6% of total output in Denmark (in 2017). Despite this, Denmark is still home to various types of agricultural production. Within animal husbandry, it includes dairy and beef cattle, pigs, poultry and fur animals – all sectors that produce mainly for export. Regarding vegetable production, Denmark is a leading producer of grass-, clover- and horticultural seeds. The agriculture and food sector as a whole represented 25% of total Danish commodity exports in 2015. 63% of the land area of Denmark is used for agricultural production – the highest share in the world according to a report from University of Copenhagen in 2017. The Danish agricultural industry is historically characterized by freehold and family ownership, but due to structural development farms have become fewer and larger. In 2020 the number of farms was approximately 33,000, of which approximately 10,000 were owned by full-time farmers.
[CS] = Keq[C]1/n The Freundlich isotherm is used when the column can bind to many different samples in the solution that needs to be purified. Because the many different samples have different binding constants to the beads, there are many different Keqs. Therefore, the Langmuir isotherm is not a good model for binding in this case.
== Formulation types == The drug form varies by its way to be administered into the body called route of administration including oral, sublingual, transdermal and inhalation delivery It can be delivered as capsules, tablets, granules, pills etc.
==== Predicting molecular fingerprints ==== CSI:FingerID predicts a probabilistic fingerprint with a variety of molecular properties from several fingerprint types. The fingerprint is predicted from the given spectrum and its corresponding fragmentation tree using deep kernel learning, which is a combination of kernel methods and deep neural networks. Not only the top scoring molecular formula but multiple high-scoring molecular formula candidates are considered.
== Research and development == In the 1970s, chemists at Dr. Karl Thomae GmbH, a subsidiary of Boehringer-Ingelheim in Germany, synthesized a variety of enol carboxamides with the aim of obtaining active ingredients with anti-inflammatory or antithrombotic properties. A compound belonging to the oxicams (UH-AC 62, meloxicam) stood out, exhibiting antiinflammatory activity in the pharmacological adjuvant arthritis model, but only low antithrombotic efficacy as measured by platelet aggregation. Dr. Karl Thomae GmbH filed the German basic patent DE2756113 (1979) and Boehringer Ingelheim US patent 4,233,299 (1980) and patents in many other countries.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.